Minh-Ha Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Minh-Ha Tran has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
Ingrid Perez-Alvarez
University of California, Irvine Department of Pathology, United States
3 shared publicationsLan Vu
3 shared publications- David M. Lin
Department of Medicine, University of California Irvine Medical Center, Orange, CA
2 shared publications Evan Trinh
2 shared publicationsIngrid Perez‐Alvarez
UC Irvine Medical Center, Orange, CA
2 shared publicationsKevin Harley
Department of Internal Medicine, Division of Nephrology and Hypertension, Irvine School of Medicine, University of California, Orange, CA, USA
2 shared publications
Latest Publications
- 6 February 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (1) , e70008
Allergic Reaction to Alteplase Dwell in Chronic Automated Red Cell Exchange Patient
Allergic reactions to intravenous, alteplase have been reported, usually in doses utilized for thrombolysis. Alteplase is also widely used for clearance of occluded catheter lumens, but allergic reactions have not been reported for this route of administration. A 14‐year‐old patient with sickle cell disease presented with an occluded apheresis port. During alteplase dwell for port occlusion, he developed an initial reaction concerning for anaphylaxis prior to automated red cell exchange, resulting in hospitalization. Findings included angioedema to the tongue and lip as well as urticaria on his abdomen and over a previous port scar, which became warm and firm. Of note, the patient also has a history of severe atopy, uncontrolled eczema, asthma, allergic rhinitis, and elevated eosinophils. The patient was referred to allergy and a skin test to alteplase was negative. The patient underwent an alteplase challenge through his catheter where he experienced anaphylaxis. Despite appropriate treatment, he again required inpatient admission. Post reaction serum tryptase level was not elevated. A clear temporal relationship to alteplase exposure and subsequent allergic reaction was documented in this case. To our knowledge, this is the first reported case of allergic reaction to intraluminal alteplase used for clearance of an occluded apheresis port. The non‐elevated tryptase level suggests a non‐IgE mediated reaction. Allergic reaction to alteplase dwell for clearance of occluded lumens can occur and is an entity apheresis providers should be aware of. Additionally, traditional skin testing may not be entirely predictive of safety upon rechallenge.
- 6 February 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (1) , e70008
Allergic Reaction to Alteplase Dwell in Chronic Automated Red Cell Exchange Patient
Allergic reactions to intravenous, alteplase have been reported, usually in doses utilized for thrombolysis. Alteplase is also widely used for clearance of occluded catheter lumens, but allergic reactions have not been reported for this route of administration. A 14‐year‐old patient with sickle cell disease presented with an occluded apheresis port. During alteplase dwell for port occlusion, he developed an initial reaction concerning for anaphylaxis prior to automated red cell exchange, resulting in hospitalization. Findings included angioedema to the tongue and lip as well as urticaria on his abdomen and over a previous port scar, which became warm and firm. Of note, the patient also has a history of severe atopy, uncontrolled eczema, asthma, allergic rhinitis, and elevated eosinophils. The patient was referred to allergy and a skin test to alteplase was negative. The patient underwent an alteplase challenge through his catheter where he experienced anaphylaxis. Despite appropriate treatment, he again required inpatient admission. Post reaction serum tryptase level was not elevated. A clear temporal relationship to alteplase exposure and subsequent allergic reaction was documented in this case. To our knowledge, this is the first reported case of allergic reaction to intraluminal alteplase used for clearance of an occluded apheresis port. The non‐elevated tryptase level suggests a non‐IgE mediated reaction. Allergic reaction to alteplase dwell for clearance of occluded lumens can occur and is an entity apheresis providers should be aware of. Additionally, traditional skin testing may not be entirely predictive of safety upon rechallenge.
- Open Access
- 26 September 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (12) , 2351-2366
Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions
The neonatal fragment crystallizable (Fc) receptor (FcRn) transports IgG across mucosal surfaces and the placenta and protects IgG from degradation. Numerous clinical trials are investigating therapeutic FcRn inhibition for various immune‐mediated neuromuscular and rheumatologic conditions; however, FcRn inhibition also represents a potential therapy for IgG‐mediated hematologic conditions (e.g., immune thrombocytopenia, autoimmune hemolytic anemia, immune thrombotic thrombocytopenic purpura, acquired hemophilia, red blood cell/platelet alloimmunization). Current evidence derived from both in vitro and in vivo studies suggests that FcRn inhibitors effectively reduce total IgG levels without impacting its production or altering the levels of other immunoglobulin isotypes. Moreover, the risk of serious adverse events, including serious infections, appears to be lower than that seen with other commonly used immunomodulatory/immunosuppressive therapies, albeit in the setting of limited clinical trial data. Ultimately, additional clinical trials that include varied patient populations are required prior to incorporating these agents into standard treatment algorithms for most hematologic conditions. However, based on the pathophysiology of IgG‐mediated hematologic disorders and the mechanism of action of FcRn inhibitors, these agents may represent a future novel therapeutic strategy for patients with hematologic conditions caused by IgG antibodies.
- 26 September 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (12) , 2351-2366
Open AccessCurrent state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions
The neonatal fragment crystallizable (Fc) receptor (FcRn) transports IgG across mucosal surfaces and the placenta and protects IgG from degradation. Numerous clinical trials are investigating therapeutic FcRn inhibition for various immune‐mediated neuromuscular and rheumatologic conditions; however, FcRn inhibition also represents a potential therapy for IgG‐mediated hematologic conditions (e.g., immune thrombocytopenia, autoimmune hemolytic anemia, immune thrombotic thrombocytopenic purpura, acquired hemophilia, red blood cell/platelet alloimmunization). Current evidence derived from both in vitro and in vivo studies suggests that FcRn inhibitors effectively reduce total IgG levels without impacting its production or altering the levels of other immunoglobulin isotypes. Moreover, the risk of serious adverse events, including serious infections, appears to be lower than that seen with other commonly used immunomodulatory/immunosuppressive therapies, albeit in the setting of limited clinical trial data. Ultimately, additional clinical trials that include varied patient populations are required prior to incorporating these agents into standard treatment algorithms for most hematologic conditions. However, based on the pathophysiology of IgG‐mediated hematologic disorders and the mechanism of action of FcRn inhibitors, these agents may represent a future novel therapeutic strategy for patients with hematologic conditions caused by IgG antibodies.
- 17 September 2024
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 44 (6) , 576-577
Health Alert: Microdose Products Leading to Acute Illness and Hospitalizations Across the United States
- 17 September 2024
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 44 (6) , 576-577
Health Alert: Microdose Products Leading to Acute Illness and Hospitalizations Across the United States
- Open Access
Eculizumab for Shiga‐toxin‐induced hemolytic uremic syndrome in adults with neurological involvement
The role of eculizumab in treating Shiga‐toxin‐producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) patients with neurological involvement remains unclear. We describe two distinctly different STEC‐HUS patients with neurologic involvement successfully managed with eculizumab, and perform a literature review of all published cases. Both patients had complete resolution of neurological symptoms after initiation of eculizumab. Eighty patients with STEC‐HUS treated with eculizumab were identified in the literature, 68.7% had complete resolution of neurological symptoms. Based on our experience and literature review, three prevailing themes were noted: 1) Early eculizumab administration optimized neurological outcomes, 2) Symptom resolution may not be immediate, neurological symptoms may initially worsen before improvement, and 3) Plasma exchange yielded no benefit. Early administration of eculizumab may reverse neurotoxicity in patients with STEC‐HUS.
Open AccessEculizumab for Shiga‐toxin‐induced hemolytic uremic syndrome in adults with neurological involvement
The role of eculizumab in treating Shiga‐toxin‐producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) patients with neurological involvement remains unclear. We describe two distinctly different STEC‐HUS patients with neurologic involvement successfully managed with eculizumab, and perform a literature review of all published cases. Both patients had complete resolution of neurological symptoms after initiation of eculizumab. Eighty patients with STEC‐HUS treated with eculizumab were identified in the literature, 68.7% had complete resolution of neurological symptoms. Based on our experience and literature review, three prevailing themes were noted: 1) Early eculizumab administration optimized neurological outcomes, 2) Symptom resolution may not be immediate, neurological symptoms may initially worsen before improvement, and 3) Plasma exchange yielded no benefit. Early administration of eculizumab may reverse neurotoxicity in patients with STEC‐HUS.
- 19 January 2024
- Published by Wiley in Transfusion
- Vol. 64 (3) , 424-427
Peripheral blood stem cell collection: Are midline catheters a viable alternative to central venous catheters?
BackgroundVascular access is a rate-limiting step for peripheral blood stem cell collection. In the absence of readily accessible superficial veins, placement of tunnelled or non-tunnelled central venous catheters (CVCs) is common. These invasive access routes create medical risks for patients and are associated with logistical challenges, thus prompting a search for alternatives. One such option is the off-label use of midline catheters.Study design and methodsWe carried out a literature search for published experience with the use of midline catheters for peripheral blood stem cell collection. Data extracted included whether collections were allogeneic or autologous, donor sex, age and weight, inlet flow rate, total blood volumes (TBV) processed, collection duration, number of collections per donor, and achievement of collection targets.ResultsThe search produced three reports (one in abstract form) comprising 19 patients and 26 collection events. Donor sex and status were provided for 18 patients; 10 were female, 8 were male, 12 were allogeneic, and 6 autologous. Median (range) for: donor age was 28 (12-59); donor body weight (kg) was 77.5 (45.4-113.4); inlet flow rate (in mL/min) was 66 (28-80); TBV processed (in mL) was 15,880 (6178-21,871); collection duration (in hours) was 5.0 (3.2-7.0); and CD34 x 106/kg collection yield was 5.9 (3.6-23.0). Target CD34 yields were achieved in 14/19 (74%) of donors with 7/19 (37%) requiring two collections days.DiscussionPeripheral blood stem cell collection does appear to be viable via midline-based catheter access, particularly for allogeneic donors and shorter collection courses. Development of institution-specific guidelines and care pathways are recommended.
- 19 January 2024
- Published by Wiley in Transfusion
- Vol. 64 (3) , 424-427
Peripheral blood stem cell collection: Are midline catheters a viable alternative to central venous catheters?
BackgroundVascular access is a rate-limiting step for peripheral blood stem cell collection. In the absence of readily accessible superficial veins, placement of tunnelled or non-tunnelled central venous catheters (CVCs) is common. These invasive access routes create medical risks for patients and are associated with logistical challenges, thus prompting a search for alternatives. One such option is the off-label use of midline catheters.Study design and methodsWe carried out a literature search for published experience with the use of midline catheters for peripheral blood stem cell collection. Data extracted included whether collections were allogeneic or autologous, donor sex, age and weight, inlet flow rate, total blood volumes (TBV) processed, collection duration, number of collections per donor, and achievement of collection targets.ResultsThe search produced three reports (one in abstract form) comprising 19 patients and 26 collection events. Donor sex and status were provided for 18 patients; 10 were female, 8 were male, 12 were allogeneic, and 6 autologous. Median (range) for: donor age was 28 (12-59); donor body weight (kg) was 77.5 (45.4-113.4); inlet flow rate (in mL/min) was 66 (28-80); TBV processed (in mL) was 15,880 (6178-21,871); collection duration (in hours) was 5.0 (3.2-7.0); and CD34 x 106/kg collection yield was 5.9 (3.6-23.0). Target CD34 yields were achieved in 14/19 (74%) of donors with 7/19 (37%) requiring two collections days.DiscussionPeripheral blood stem cell collection does appear to be viable via midline-based catheter access, particularly for allogeneic donors and shorter collection courses. Development of institution-specific guidelines and care pathways are recommended.
- 29 November 2023
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 33 (2) , 247-256
Thrombotic microangiopathy – the importance of a multidisciplinary approach
Purpose of review: The purpose of this review is to highlight the importance of a multidisciplinary thrombotic microangiopathies (TMA) Team. This goal will be accomplished through review of the complement system, discuss various causes of thrombotic microangiopathies (TMA), and aspects of their diagnosis and management. In so doing, readers will gain an appreciation for the complexity of this family of disorders and realize the benefit of a dedicated multidisciplinary TMA Team. Recent findings: TMA causes derive from multiple specialty areas, are difficult to timely recognize, pose complex challenges, and require multidisciplinary management. Hematopoietic stem cell transplant-associated TMA (TA-TMA) and TA-TMA related multiorgan dysfunction syndrome (TA-TMA MODS) are areas of burgeoning research; use of complement testing and eculizumab precision-dosing has been found to better suppress complement activity in TA-TMA than standard eculizumab dosing. Newer tests are available to risk-stratify obstetric patients at risk for severe pre-eclampsia, whose features resemble those of TA-TMA MODS. Numerous disorders may produce TMA-like findings, and a systematic approach aids in their identification. TMA Teams elevate institutional awareness of increasingly recognized TMAs, will help expedite diagnostic and therapeutic interventions, and create pathways to future TMA-related research and facilitate access to clinical trials. Summary: Establishment of a TMA-Team is valuable in developing the necessary institutional expertise needed to promptly recognize and appropriately manage patients with TMA.
- 29 November 2023
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 33 (2) , 247-256
Thrombotic microangiopathy – the importance of a multidisciplinary approach
Purpose of review: The purpose of this review is to highlight the importance of a multidisciplinary thrombotic microangiopathies (TMA) Team. This goal will be accomplished through review of the complement system, discuss various causes of thrombotic microangiopathies (TMA), and aspects of their diagnosis and management. In so doing, readers will gain an appreciation for the complexity of this family of disorders and realize the benefit of a dedicated multidisciplinary TMA Team. Recent findings: TMA causes derive from multiple specialty areas, are difficult to timely recognize, pose complex challenges, and require multidisciplinary management. Hematopoietic stem cell transplant-associated TMA (TA-TMA) and TA-TMA related multiorgan dysfunction syndrome (TA-TMA MODS) are areas of burgeoning research; use of complement testing and eculizumab precision-dosing has been found to better suppress complement activity in TA-TMA than standard eculizumab dosing. Newer tests are available to risk-stratify obstetric patients at risk for severe pre-eclampsia, whose features resemble those of TA-TMA MODS. Numerous disorders may produce TMA-like findings, and a systematic approach aids in their identification. TMA Teams elevate institutional awareness of increasingly recognized TMAs, will help expedite diagnostic and therapeutic interventions, and create pathways to future TMA-related research and facilitate access to clinical trials. Summary: Establishment of a TMA-Team is valuable in developing the necessary institutional expertise needed to promptly recognize and appropriately manage patients with TMA.
- 3 November 2023
- Published by Wiley in Transfusion
- Vol. 63 (12) , 2341-2350
Historic and emerging trends in transfusion medicine: Maintaining relevance as a specialty
- 3 November 2023
- Published by Wiley in Transfusion
- Vol. 63 (12) , 2341-2350
Historic and emerging trends in transfusion medicine: Maintaining relevance as a specialty